What MASH is
MASH, formerly called NASH, is a serious liver disease in which fat buildup drives inflammation and scarring (fibrosis). Left untreated it can progress to cirrhosis, liver failure, or liver cancer. It affects roughly 6% of U.S. adults and is closely linked to obesity, type 2 diabetes, and abnormal lipids — the same metabolic drivers semaglutide already targets.
The ESSENCE evidence
The approval rests on Part 1 (72-week) results of the randomized, double-blind ESSENCE trial. A longer Part 2, running to 240 weeks, is designed to confirm whether these histologic gains translate into fewer liver-related clinical events, with results expected around 2029.
Who it is for
| Group | Relevance |
|---|---|
| Adults with MASH + F2-F3 fibrosis | Indicated population |
| MASH with cirrhosis | Not included in the indication |
| Weight or CV patients | Separate existing Wegovy indications |
| Compounded semaglutide users | MASH indication applies to FDA-approved Wegovy only |
Why it is significant
MASH has had very few approved drug therapies. Adding a widely used GLP-1 with an established safety profile expands options for a disease that is both common and under-treated. It also reinforces a broader theme in 2025-2026: GLP-1 medicines are moving well beyond weight loss into cardiovascular, kidney, sleep-apnea, and now liver indications.
Safety notes
The main safety concern in ESSENCE was gastrointestinal side effects, consistent with semaglutide’s known profile, with a small share of participants discontinuing. The MASH indication does not change how the drug is dosed for weight or cardiovascular use, and treatment decisions for liver disease should be made with a clinician who can stage fibrosis and monitor response.
Compounded caveat
This indication belongs to FDA-approved Wegovy, not compounded semaglutide. Compounded products are not FDA-approved and were not studied in ESSENCE, so the MASH data should not be assumed to apply to them. Patients interested in semaglutide for liver disease should pursue the approved product under medical supervision. See our side-effects guide for tolerability context.
Access and what to ask
Because the MASH indication is new, coverage and prescribing are still settling. Patients with suspected MASH should not self-diagnose from symptoms alone; fibrosis staging typically involves blood-based tests, imaging such as elastography, and sometimes biopsy. If you have obesity or type 2 diabetes plus elevated liver enzymes, that is a reasonable prompt to ask a clinician whether liver assessment is warranted. For those who qualify, the practical questions are whether insurance covers Wegovy for the MASH indication specifically, how liver response will be monitored over time, and how the drug fits with any other GLP-1 or metabolic treatment already in place. The approval is an accelerated one confirmed by ongoing study, so guidance may evolve as longer-term ESSENCE data arrive around 2029.
Frequently asked questions
Is Wegovy approved for liver disease?
Yes. On August 15, 2025, the FDA granted accelerated approval for Wegovy to treat MASH with moderate-to-advanced fibrosis (F2-F3), excluding cirrhosis.
How well did it work?
In ESSENCE, 62.9% of semaglutide patients achieved MASH resolution without worsening fibrosis, and 33% achieved both resolution and fibrosis improvement versus 16% on placebo.
Is it the first drug for MASH?
It is the first GLP-1 approved for MASH. Resmetirom, a different drug class, was approved for MASH in 2024.
Does this apply to compounded semaglutide?
No. The MASH indication applies to FDA-approved Wegovy only; compounded semaglutide is not FDA-approved and was not studied.
References
- FDA. FDA approves treatment for serious liver disease known as MASH. August 15, 2025.
- Novo Nordisk. Wegovy approved in the US for noncirrhotic MASH. August 15, 2025.
- AJMC. FDA approves semaglutide for MASH with fibrosis. 2025.
- Sanyal AJ et al. Phase 3 trial of semaglutide in MASH (ESSENCE). NEJM, 2025.